Quick Answer
Tesamorelin has the stronger case for visceral-fat and abdominal-body-composition research. Sermorelin is a GHRH(1-29)-amide fragment, while tesamorelin is a stabilized GHRH analog with prescription-label context and randomized trials showing reductions in visceral adipose tissue.
If the question is broad GH-axis stimulation, both belong in the conversation. If the question is belly fat, visceral fat, and clinically measured abdominal-body-composition change, tesamorelin is the more compelling peptide.
Explore the AminoRank tesamorelin profileReview linked studies, category details, and vendor availability for tesamorelin.View tesamorelin profileSame Family, Different Research Identity
Tesamorelin and sermorelin are often compared because both are tied to growth-hormone-releasing hormone signaling. They both work upstream of growth hormone rather than supplying growth hormone directly.
The difference is in design and evidence. NCBI MeSH describes sermorelin as the biologically active fragment of human growth-hormone-releasing factor, consisting of GHRH(1-29)-amide. Tesamorelin is a growth-hormone-releasing factor analog with an approved prescription context for reducing excess abdominal fat in adults with HIV and lipodystrophy.
| Feature | Tesamorelin | Sermorelin |
|---|---|---|
| Peptide category | GHRH/GHRF analog | GHRH(1-29)-amide fragment |
| Best-known use case | Visceral abdominal-fat reduction in HIV lipodystrophy context | GH stimulation and GH-deficiency diagnostic or treatment history |
| Evidence strength for visceral fat | Stronger, with randomized trials | Much weaker for this specific outcome |
| Reader-fit | Abdominal body composition and visceral-fat research | General GH-axis research interest |
Why Tesamorelin Wins For Visceral Fat
Tesamorelin's advantage is not marketing. It has clinical data. In a randomized trial of adults with HIV and central fat accumulation, tesamorelin reduced visceral adipose tissue by 10.9% at six months compared with 0.6% with placebo. In extension data, continued treatment was associated with about an 18% reduction over 12 months.
That outcome is exactly what most comparison readers want to know. Sermorelin may be relevant to GH-axis research, but it does not bring the same focused visceral-fat trial record.
Why Sermorelin Still Matters
Sermorelin still matters. It is a classic GHRH fragment and has a long history in GH-stimulation contexts. It is often discussed when the goal is supporting endogenous GH release rather than targeting a specific abdominal-fat endpoint.
That makes sermorelin a cleaner fit for broad GH-axis conversations. Tesamorelin is the better fit when the reader specifically cares about visceral abdominal-fat research.
Mechanism Comparison
Both peptides stimulate the pituitary through GHRH-related signaling. That upstream mechanism is why both are often positioned differently from direct HGH. The body is being signaled to release growth hormone rather than being supplied with growth hormone itself.
Tesamorelin's stronger clinical identity comes from what happened after that signal in trials: visceral-fat reduction, waist-profile improvement, and triglyceride findings in longer-term data.
Which Is Better?
For visceral fat, tesamorelin is better supported. For broad GH-axis interest, the answer depends on the research goal. Sermorelin is simpler and historically familiar. Tesamorelin is more specialized and clinically stronger for abdominal body composition.
The strongest fair answer is this: sermorelin is a useful GH-axis comparison point, but tesamorelin is the better peptide when the target is abdominal visceral fat and body-composition evidence.
Buying Context
When comparing research listings, be sure the product name matches the goal. Tesamorelin, sermorelin, and blends can sit near each other in vendor catalogs, but they are not interchangeable compounds. Product clarity matters before price.
Tesamorelin Vendors With Documentation Signals
View all Tesamorelin vendors| Vendor | Country | COAs | Rating | Reviews | Notes | Website |
|---|---|---|---|---|---|---|
| LA Peptides | USA | Yes | 5.0 | 1 | Verified listing | Buy |
| NextGenPeps | USA | Yes | 5.0 | 1 | Verified listing | Buy |
| Alpha Peptides | USA | Yes | 0.0 | 0 | Verified listing | Buy |
| Ascension Peptides | USA | Yes | 0.0 | 0 | Verified listing | Buy |
| BioCollex | USA | Yes | 0.0 | 0 | Verified listing | Buy |
| Coastal Peptides | USA | Yes | 0.0 | 0 | Verified listing | Buy |
FAQ
Is tesamorelin stronger than sermorelin?
For visceral-fat research, tesamorelin has a stronger evidence base. For general GH-axis stimulation, they are better compared by research goal.
Are tesamorelin and sermorelin the same thing?
No. They are related GHRH peptides, but they are not the same compound.
Why do people compare sermorelin vs tesamorelin?
Both stimulate growth hormone release through GHRH-related signaling, so they naturally appear in GH peptide comparisons.
Which has better clinical data?
Tesamorelin has stronger clinical data for visceral abdominal-fat reduction.